Leukemia Posts on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

Updates to NCCN guidelines for acute myeloid leukemia

Updates to NCCN guidelines for acute myeloid leukemia

Posted by on Apr 30, 2021 in Leukemia | 0 comments

In a nutshell This article aimed to outline updates to the National Comprehensive Cancer Network (NCCN) guidelines for the treatment of acute myeloid leukemia (AML).  Some background The NCCN Guidelines for AML provide recommendations for the diagnosis and treatment of AML. The recommendations are based on clinical...

Read More

Inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory acute lymphoblastic leukemia

Inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory acute lymphoblastic leukemia

Posted by on Apr 24, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the combination of inotuzumab ozogamicin (InO; Besponsa) and mini-hyper-CVD (cyclophosphamide and dexamethasone at 50% dose reduction, no anthracycline, methotrexate at 75% dose reduction, cytarabine at 0.5 g/m2  x 4 doses) with or without blinatumomab (Blincyto) in patients with...

Read More

Idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia in a real life setting

Idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia in a real life setting

Posted by on Apr 24, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of idelalisib (Zydelig) and rituximab (Rituxan) in patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) in a real-life setting.  This study concluded that this treatment in a real-life setting was just as effective as in a clinical trial...

Read More

Is long-term treatment-free remission possible after frontline nilotinib treatment in patients with chronic phase chronic myeloid leukemia?

Is long-term treatment-free remission possible after frontline nilotinib treatment in patients with chronic phase chronic myeloid leukemia?

Posted by on Apr 21, 2021 in Leukemia | 0 comments

In a nutshell This study provided an updated 5-year assessment of treatment-free remission (TFR) after frontline nilotinib (Tasigna) treatment in patients with chronic-phase (CP) chronic myeloid leukemia (CML). The data showed sustained, long-term high TFR rates with effectiveness and safety in these patients. Some background Long-term treatments...

Read More

Evaluating the effectiveness and safety of inotuzumab ozogamicin for patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Evaluating the effectiveness and safety of inotuzumab ozogamicin for patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Posted by on Apr 18, 2021 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of inotuzumab ozogamicin (Besponsa; INO) in patients with relapsed/refractory (r/r) acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The data showed that the treatment had good effectiveness and manageable side effects for these patients. Some background A high number...

Read More

Outcomes for children with acute myeloid leukemia treated with the MASPORE 2006 protocol

Outcomes for children with acute myeloid leukemia treated with the MASPORE 2006 protocol

Posted by on Apr 11, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcomes for pediatric patients with acute myeloid leukemia (AML) treated with the MASPORE 2006 protocol.  This study concluded that this treatment protocol provided improved outcomes for these patients when compared to earlier treatment protocols.  Some background From 1997 to 2006, children...

Read More

Comparing nilotinib and dasatinib as second line treatment in patients with chronic myeloid leukemia in a real-life setting

Comparing nilotinib and dasatinib as second line treatment in patients with chronic myeloid leukemia in a real-life setting

Posted by on Apr 11, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to compare dasatinib (Sprycel) and nilotinib (Tasigna) as second-line treatments for patients with chronic-phase (CP) chronic myeloid leukemia (CML) in a real-life setting.   This study concluded that both dasatinib and nilotinib are equally effective and well...

Read More

Comparing ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukemia

Comparing ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukemia

Posted by on Apr 11, 2021 in Leukemia | 0 comments

In a nutshell This study investigated the safety and effectiveness of adding ublituximab (TG-1101) to ibrutinib (Imbruvica) treatment for patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL). The data showed that adding ublituximab to ibrutinib significantly improved the overall response rate compared to ibrutinib alone...

Read More

Combining venetoclax and navitoclax with chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma

Combining venetoclax and navitoclax with chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma

Posted by on Mar 28, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of venetoclax (Venclexta) and low-dose navitoclax (ABT-263) in combination with chemotherapy in patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL).  This study concluded that this treatment option was well tolerated and...

Read More